<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Thiotepa: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Thiotepa: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Thiotepa: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9992" href="/d/html/9992.html" rel="external">see "Thiotepa: Drug information"</a> and <a class="drug drug_patient" data-topicid="11432" href="/d/html/11432.html" rel="external">see "Thiotepa: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F50109503"><span class="drugH1">ALERT: US Boxed Warning</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Myelosuppression:</b> Thiotepa may cause severe marrow suppression, and high doses may cause marrow ablation with resulting infection or bleeding. Monitor hematologic laboratory parameters. Hematopoietic progenitor (stem) cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression after high doses of thiotepa.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Carcinogenicity:</b> Thiotepa should be considered potentially carcinogenic in humans.</p></div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F50047945"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Tepadina</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868400"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Tepadina</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1050283"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Alkylating Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F10245670"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing and frequency may vary by protocol; refer to individual protocols. In pediatric patients, dosing may be based on either BSA (mg/m<sup>2</sup>) or weight (mg<b>/kg</b>); use extra precaution to verify dosing parameters during dosage calculations.</p>
<p style="text-indent:0em;margin-top:2em;">Antiemetics may be recommended for prevention of nausea and vomiting. In pediatric patients, doses ≥300 mg/m<sup>2</sup> are associated with a high emetic potential and doses &lt;300 mg/m<sup>2</sup> are associated with a low emetic potential (POGO [Dupuis 2011]; POGO [Paw Cho Sing 2019]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="68683657-2d2b-4ea4-84c6-b5019893d803">CNS malignancy, newly diagnosed, high-dose chemotherapy followed by autologous stem cell rescue, consolidation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>CNS malignancy, newly diagnosed, high-dose chemotherapy followed by autologous stem cell rescue (ASCR), consolidation:</b> Infants ≥6 months and Children &lt;3 years: IV: 10 mg/<b>kg</b>/dose daily for 2 days on days 0 and 1 in combination with carboplatin, followed by ASCR (Cohen 2015).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e145f958-067a-4f5d-be49-c2d44994eb9f">CNS malignancy, recurrent or refractory followed by autologous stem cell rescue</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>CNS malignancy, recurrent or refractory followed by autologous stem cell rescue (ASCR):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children ≤25 kg: IV: 6.67 mg/<b>kg</b>/dose daily for 3 days followed by ASCR approximately 72 hours after the third dose. A second cycle of thiotepa/ASCR was administered at least 28 days after completion of first course if sufficient hematologic recovery and no tumor progression (Osorio 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents &gt;25 kg: IV: 200 mg/m<sup>2</sup>/dose daily for 3 days followed by ASCR approximately 72 hours after the third dose. A second cycle of thiotepa/ASCR was administered at least 28 days after completion of first course if sufficient hematologic recovery and no tumor progression (Osorio 2018).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="019116fd-2d13-469e-aed7-0a7f23583e80">Hematopoietic stem cell transplant, autologous, conditioning regimen</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic stem cell transplant (HSCT), autologous, conditioning regimen:</b> Infants, Children, and Adolescents: IV: 300 mg/m<sup>2</sup>/dose daily for 3 days beginning 8 days prior to transplant <b>OR </b>300 mg/m<sup>2</sup>/dose daily for 3 days beginning 5 days prior to transplant in combination with other preconditioning therapies (protocols vary). For infants, some protocols report using a dose of 10 mg/<b>kg</b>/dose daily for 3 days (Chi 2004; Dunkel 2010; Fangusaro 2008; Finlay 2008; Gilheeney 2010; Grodman 2009; Guidi 2020; Kushner 2001).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8fad551e-9cee-441a-b6c0-b51fae441a93">Hematopoietic stem cell transplant for acute leukemias; allogeneic, conditioning regimens</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic stem cell transplant (HSCT) for acute leukemias; allogeneic, conditioning regimens:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treosulfan/fludarabine/thiotepa regimen</i>: Infants, Children, and Adolescents: IV: 5 mg/<b>kg</b>/dose daily for 2 days starting on day −2 in combination with treosulfan and fludarabine (Kalwak 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>TBI-Thio-Cy regimen</i>: Children and Adolescents: IV: 5 mg/<b>kg</b>/dose for 2 doses over 1 or 2 days beginning either 7 or 4 days prior to transplant depending on protocol in combination with total body irradiation and cyclophosphamide (Bunin 2005; Zecca 1999).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Clo-Mel-Thio</i>: Children and Adolescents: IV: 10 mg/<b>kg</b>/dose daily for 1 day beginning 4 days prior to transplant in combination with clofarabine and melphalan; patients were receiving second or third HSCT (Spitzer 2016).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="76e091f0-7eb9-48d0-a984-e5eead3ce9c7">Hematopoietic stem cell transplant for beta-thalassemia, class 3; allogeneic conditioning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic stem cell transplant (HSCT) for beta-thalassemia, class 3; allogeneic conditioning: </b>Infants, Children, and Adolescents: Tepadina: IV: 5 mg/<b>kg</b>/dose every 12 hours for 2 doses 6 days prior to HSCT in combination with high-dose busulfan and cyclophosphamide (manufacturer's labeling).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="219bdc10-fcf6-40af-ad6e-5900449794ea">Hematopoietic stem cell transplant for neuroblastoma; autologous, conditioning regimen</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic stem cell transplant (HSCT) for neuroblastoma; autologous, conditioning regimen:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single transplant:</i> Children and Adolescents: IV: 300 mg/m<sup>2</sup>/dose daily for 3 days for a total dose of 900 mg/m<sup>2</sup> beginning 8 days prior to transplant (day −8, −7, −6) in combination with carboplatin and topotecan (Kushner 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tandem transplant</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children ≤12 kg: IV: 10 mg/<b>kg</b>/dose daily for 3 days beginning 7 days before the first transplant and followed by cyclophosphamide (Park 2019).</p>
<p style="text-indent:-2em;margin-left:6em;">Children &gt;12 kg and Adolescents: IV: 300 mg/m<sup>2</sup>/dose daily for 3 days beginning 7 days before the first transplant and followed by cyclophosphamide (Park 2019).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="03ea73a1-1dd9-4ff3-b187-67f9ac3a1134">Hematopoietic stem cell transplant for nonmalignant hematologic disorders, allogeneic, conditioning regimens</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic stem cell transplant (HSCT) </b>
<b>for nonmalignant hematologic disorders, allogeneic, conditioning regimens: </b>Infants, Children, and Adolescents: IV: 10 mg/<b>kg</b>/dose as a single dose in a fludarabine-based combination regimen (Mussetti 2016).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d1911edc-bd0e-468e-8dbc-a1dc3e8766cc">Leukemia, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leukemia, relapsed or refractory:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>TVTC regimen: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants: IV: 0.5 mg/<b>kg</b>/dose over 4 hours on day 2 of a 28-day regimen in combination with topotecan, clofarabine, and vinorelbine; in the trial, the youngest patient was 8 months of age (Steinherz 2010).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: IV: 15 mg/m<sup>2</sup>/dose over 4 hours on day 2 of a 28-day regimen in combination with topotecan, clofarabine, vinorelbine (Shukla 2014; Steinherz 2010).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> The presented dosing adjustments are based on experience in adult patients. Refer to specific protocol for management in pediatric patients if available.</p>
<p style="text-indent:-2em;margin-left:4em;">Adult:</p>
<p style="text-indent:-2em;margin-left:6em;">Central nervous system toxicity, severe or life-threatening: Discontinue thiotepa and provide supportive care.</p>
<p style="text-indent:-2em;margin-left:6em;">Hypersensitivity reactions (eg, anaphylaxis or other clinically significant reaction): Discontinue thiotepa and manage as appropriate; monitor until signs/symptoms resolve.</p></div>
<div class="block dorp drugH1Div" id="F51192733"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; reduced dose may be warranted. Use may be contraindicated with existing renal impairment and should be limited to cases where benefit outweighs risk.</p></div>
<div class="block dohp drugH1Div" id="F51192734"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; reduced dose may be warranted. Use may be contraindicated with existing hepatic impairment and should be limited to cases where benefit outweighs risk.</p></div>
<div class="block doa drugH1Div" id="F227170"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9992" href="/d/html/9992.html" rel="external">see "Thiotepa: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Antiemetics are recommended to prevent nausea and vomiting; thiotepa (IV) is associated with a moderate emetic potential (ASCO [Hesketh 2020]; MASCC/ESMO [Roila 2016]). Although included in the manufacturer's labeling as approved uses, other contemporary therapies have replaced the use of thiotepa for the treatment of papillary bladder, ovarian, and breast cancers, as well as malignant intracavitary effusions.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="01c38604-85af-44f0-809c-dcfd59c49b4c">Hematopoietic cell transplant conditioning regimen for CNS malignancy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic</b>
<b> cell transplant conditioning regimen for CNS malignancy (off-label use):</b>
<b>IV:</b> 250 mg/m<sup>2</sup>/day for 3 days beginning 9 days prior to transplant (in combination with busulfan and cyclophosphamide) (Soussain 2008; DeFilipp 2017) <b>or</b> 150 mg/m<sup>2</sup>/dose every 12 hours for 6 doses, followed by cell reinfusion 96 hours after completion of thiotepa (Abrey 2006).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="82b24863-6d8c-471d-9ecb-888c36593d38">Leptomeningeal metastases</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leptomeningeal metastases (off-label use/route): Intrathecal:</b> 10 mg twice a week (on days 1 and 4 each week) for 8 weeks (Grossman 1993).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991150"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; decreased renal excretion may result in increased thiotepa and TEPA plasma concentrations and increased toxicity. Monitor patients with moderate (CrCl 30 to 59 mL/minute) to severe (CrCl &lt;30 mL/minute) impairment for toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Thiotepa is dialyzable.</p></div>
<div class="block doha drugH1Div" id="F50988503"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; thiotepa is extensively hepatically metabolized. Moderate (bilirubin &gt;1.5 to 3 times ULN and any AST) or severe (bilirubin &gt;3 times ULN and any AST) impairment may result in increased plasma concentrations and increased toxicity. Monitor closely for toxicity.</p></div>
<div class="block adr drugH1Div" id="F227141"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">As a preparative regimen prior to allogeneic or autologous hematopoietic progenitor cell transplantation:</p>
<p style="text-indent:-2em;margin-left:4em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:6em;">Central nervous system: Intracranial hemorrhage, seizure</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Mucositis</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Anemia, hemorrhage, neutropenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:6em;">Hepatic: Increased serum ALT, increased serum AST, increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:6em;">Infection: Cytomegalovirus disease</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Pneumonia</p>
<p style="text-indent:-2em;margin-left:2em;">Other approved/nonapproved uses:</p>
<p style="text-indent:-2em;margin-left:6em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:8em;">Dermatologic: Alopecia, contact dermatitis, dermatitis, skin depigmentation, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:8em;">Central nervous system: Dizziness, fatigue, headache</p>
<p style="text-indent:-2em;margin-left:8em;">Endocrine &amp; metabolic: Amenorrhea</p>
<p style="text-indent:-2em;margin-left:8em;">Gastrointestinal: Abdominal pain, anorexia, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:8em;">Genitourinary: Cystitis, dysuria, hemorrhagic cystitis, inhibition of Spermatogenesis, urinary retention</p>
<p style="text-indent:-2em;margin-left:8em;">Hypersensitivity: Anaphylactic shock, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:8em;">Infection: Infection</p>
<p style="text-indent:-2em;margin-left:8em;">Local: Pain at injection site</p>
<p style="text-indent:-2em;margin-left:8em;">Neuromuscular &amp; skeletal: Weakness</p>
<p style="text-indent:-2em;margin-left:8em;">Ophthalmic: Blurred vision, conjunctivitis</p>
<p style="text-indent:-2em;margin-left:8em;">Respiratory: Asthma, laryngeal edema, wheezing</p>
<p style="text-indent:-2em;margin-left:8em;">Miscellaneous: Febrile reaction</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abnormal gait, acute myelocytic leukemia, acute respiratory distress, acute sinusitis, amnesia, apathy, aphasia, arteriosclerosis (pulmonary arteriopathy), ascites, aspiration, ataxia, behavioral problems, blepharoptosis, blindness, blood coagulation disorder, blood platelet disorder (refractoriness to transfusion), bone marrow aplasia, bone marrow depression (bone marrow transplant rejection), bradycardia, brain disease, candidiasis, capillary leak syndrome, cardiac failure, cerebrovascular accident, cognitive dysfunction, coma, confusion, cranial nerve palsy, deafness, delirium, depression, diarrhea, disorientation, drowsiness, dysphagia, dyspnea on exertion, encephalitis, enterocolitis, epstein-barr infection, fever, forgetfulness, fungal infection, gastritis, gastroenteritis, gastrointestinal hemorrhage, hallucination, hematuria, hemiplegia, hepatomegaly, hyponatremia, hypotonia, immunosuppression, infection due to enterococcus, interstitial pulmonary disease, klebsiella species, lesion (including central nervous system and white matter), leukemia (recurrent), leukoencephalopathy, lower respiratory tract infection (viral), lymphoproliferative disorder (posttransplant), malaise, malignant lymphoma (including central nervous system lymphoma), malignant neoplasm (recurrence), malignant neoplasm of breast (metastatic), memory impairment, motor dysfunction, mouth disease (palatal disorder), myelodysplastic syndrome, neoplasm (metastatic), neurotoxicity, pain, papilledema, paralysis (retrobulbar), paresis (quadriparesis), pericardial effusion, pericarditis, pneumonitis, pseudomonas infection, psychomotor retardation, pulmonary aspergillosis, pulmonary disease, pulmonary hypertension, pulmonary veno-occlusive disease, pure red cell aplasia, renal failure, respiratory distress, respiratory tract infection, sepsis, septic shock, speech disturbance, staphylococcal bacteremia, staphylococcal infection, Stevens-Johnson Syndrome, strabismus, subarachnoid hemorrhage, subdural hematoma, suicidal ideation, thrombotic thrombocytopenic purpura (cerebral), toxic epidermal necrolysis, toxic nephrosis, tremor, urinary tract infection, vasodilation (cerebral ventricle), ventricular hypertrophy, weight gain</p></div>
<div class="block coi drugH1Div" id="F227155"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Known hypersensitivity (allergy) to thiotepa or any component of the formulation; concomitant use with live or attenuated vaccines (Tepadina).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Pregnancy; breastfeeding.</p></div>
<div class="block war drugH1Div" id="F227138"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Myelosuppression (leukopenia, thrombocytopenia, and anemia) may commonly occur, particularly when used as part of the preparative regimen for hematopoietic cell transplantation (HCT) or in patients with compromised bone marrow function. Do not initiate the HCT conditioning regimen if a donor is not available. Infection or bleeding may occur; death due to septicemia and hemorrhage has occurred. Myelosuppression (including fatal cases) has also been reported with intravesicular administration (due to systemic absorption).</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: Fatal encephalopathy has been reported in patients receiving high-dose thiotepa. Headache, apathy, psychomotor retardation, disorientation, confusion, amnesia, hallucinations, drowsiness, somnolence, seizures, coma, inappropriate behavior, and forgetfulness have also been reported (may be dose dependent). CNS toxicity, including seizures and intracranial hemorrhage was reported in pediatric patients who receive the recommended dose in combination with busulfan and cyclophosphamide as a conditioning regimen for beta thalassemia; do not exceed the recommended dose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: In patients receiving high-dose thiotepa, the parent drug and/or its active metabolites may be partially excreted through the skin. Thiotepa may cause skin discoloration, pruritus, blistering, desquamation, and peeling (may be more severe in skin folds, groin, axillae, and neck areas, and under dressings). Change occlusive dressing and clean covered skin at least twice daily during and for 48 hours after thiotepa administration (when used as a component of the HCT preparative regimen). Patients should shower/bathe in water at least twice daily through 48 hours after receiving thiotepa. Change bed sheets daily. Avoid topical creams/ointments during thiotepa therapy as to not impede excretion (Van Schandevy 2019). Accidental thiotepa exposure is also associated with skin reactions; wash skin thoroughly with soap and water and flush mucous membranes if skin and/or mucous membrane contact occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic sinusoidal obstruction syndrome: Hepatic sinusoidal obstruction syndrome (SOS, also called veno-occlusive disease [VOD]) may occur in patients receiving thiotepa in combination with busulfan and cyclophosphamide as a preparative regimen prior to HCT. Monitor for signs/symptoms of hepatic SOS through day +28 of transplant; provide supportive care if SOS develops.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Clinically significant hypersensitivity reactions (including anaphylaxis) have occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary malignancies: Thiotepa is potentially carcinogenic; myelodysplastic syndrome and acute myeloid leukemia (AML) have been reported. There is an increased risk of secondary malignancies with thiotepa use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Vaccines: Do not administer live or attenuated viral or bacterial vaccines until the immunosuppressive effects of thiotepa have resolved.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Intrathecal safety: When used for intrathecal administration (off-label route), should not be prepared during the preparation of any other agents. After preparation, keep intrathecal medications in an isolated location or container clearly marked with a label identifying as "intrathecal" use only. Delivery of intrathecal medications to the patient should only be with other medications also intended for administration into the central nervous system (ASCO/ONS [Jacobson 2009]).</p></div>
<div class="block foc drugH1Div" id="F30124467"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 15 mg (1 ea); 100 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tepadina: 15 mg (1 ea); 100 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 15 mg (1 ea); 100 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F227134"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323960"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Tepadina Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $1,080.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $5,640.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Thiotepa Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $240.00 - $965.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $2,820.00 - $5,125.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868401"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tepadina: 15 mg (1 ea); 100 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 15 mg (1 ea); 100 mg (1 ea)</p></div>
<div class="block admp drugH1Div" id="F52613922"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">In children, thiotepa is associated with a high emetic potential at doses ≥300 mg/m<sup>2</sup>; antiemetics are recommended to prevent nausea and vomiting (POGO [Dupuis 2011]; POGO [Paw Cho Sing 2019]). Ensure increased showers/baths conducted during therapy if applicable (see "Warnings/Precautions").</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: Must be diluted prior to administration; high doses (pediatric) are administered as an IV infusion (eg, over 2- to 4-hour infusion). Infusion times may vary by protocol; refer to specific protocols. For Tepadina (and associated generic products), administer using a 0.2 micron in-line filter; flush line prior to and after infusion with ~5 mL NS.</p></div>
<div class="block adm drugH1Div" id="F227152"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Antiemetics may be recommended to prevent nausea and vomiting; thiotepa (IV) is associated with a moderate emetic potential in adults (ASCO [Hesketh 2020]; MASCC/ESMO [Roila 2016]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer over 3 hours via a central line (when administering as part of the preparative regimen for hematopoietic cell transplantation in class 3 beta-thalassemia). Infusion times may vary by protocol or dose for off-label uses; refer to specific protocols. Filtering does not alter thiotepa potency. <i>Tepadina:</i> Administer using a 0.2 micron in-line filter; flush line prior to and after infusion with ~5 mL NS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intrathecal route (off-label use/route):</b> Was administered in 10 mL (preservative free) buffered solutions (Grossman 1993).</p></div>
<div class="block hazard drugH1Div" id="F49132739"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block sts drugH1Div" id="F227163"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Tepadina: Store intact vials at 2°C to 8°C (36°F to 46°F). Protect from light; do not freeze. Reconstituted solution (10 mg/mL) is stable for 8 hours when stored at 2°C to 8°C (36°F to 46°F). Solution further diluted for infusion in NS is stable for 24 hours when stored at 2°C to 8°C (36°F to 46°F), or for 4 hours when stored at 25°C (77°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Generic product labeling: Store intact vials at 2°C to 8°C (36°F to 46°F). Protect from light. Reconstituted solutions (10 mg/mL) are stable for up to 8 hours when stored under refrigeration. Solutions further diluted for infusion in NS should be used immediately.</p>
<p style="text-indent:-2em;margin-left:2em;">Intrathecal thiotepa (off-label use/route): After preparation, keep intrathecal medications in an isolated location or container clearly marked with a label identifying as "intrathecal" use only.</p></div>
<div class="block usep drugH1Div" id="F53569096"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">To reduce the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation in patients with class 3 beta-thalassemia (Tepadina: FDA approved in pediatric patients ≥1 month of age); treatment of superficial tumors of the bladder (FDA approved in adults); palliative treatment of adenocarcinoma of breast or ovary (FDA approved in adults); control of pleural, pericardial, or peritoneal effusions caused by metastatic tumors (FDA approved in adults); has also been used as part of a conditioning regimen prior to autologous or allogeneic hematopoietic stem cell transplantation.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Although included in the manufacturer's labeling as approved uses in adults, other contemporary therapies have replaced the use of thiotepa for the treatment of papillary bladder, ovarian, and breast cancers, as well as for malignant intracavitary effusions.</p></div>
<div class="block mst drugH1Div" id="F3402289"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Thiotepa may be confused with thioguanine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<i>Intrathecal medication safety:</i> The American Society of Clinical Oncology (ASCO)/Oncology Nursing Society (ONS) chemotherapy administration safety standards (ASCO/ONS [Jacobson 2009]) encourage the following safety measures for intrathecal chemotherapy:</p>
<p style="text-indent:-2em;margin-left:6em;">• Intrathecal medication should not be prepared during the preparation of any other agents</p>
<p style="text-indent:-2em;margin-left:6em;">• After preparation, keep in an isolated location or container clearly marked with a label identifying as "intrathecal" use only</p>
<p style="text-indent:-2em;margin-left:6em;">• Delivery to the patient should only be with other medications also intended for administration into the central nervous system</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F227199"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F227143"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2B6 Substrates (High risk with Inhibitors): Thiotepa may increase the serum concentration of CYP2B6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May increase serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Thiotepa.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May increase serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inducers (Strong) may decrease the serum concentration of Thiotepa. Management: Thiotepa prescribing information recommends avoiding concomitant use of thiotepa and strong CYP3A4 inducers. If concomitant use is unavoidable, monitor for adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May decrease serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Thiotepa.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May decrease serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Thiotepa. Management: Avoid coadministration of thiotepa and strong CYP3A4 inhibitors. If concomitant use cannot be avoided, monitor for thiotepa adverse effects and decreased efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53623816"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to therapy initiation in patients who could become pregnant. Effective contraception should be used during treatment and for at least 6 months after the final dose. Patients with partners who could become pregnant should use effective contraception during therapy and for at least 1 year after the final dose.</p></div>
<div class="block pri drugH1Div" id="F3881813"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action, and data from animal reproduction studies, in utero exposure to thiotepa may cause fetal harm.</p></div>
<div class="block mopp drugH1Div" id="F53569097"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential and platelet count (baseline, frequently throughout therapy), uric acid, urinalysis, renal and hepatic function tests. Evaluate pregnancy status prior to treatment. Monitor for signs/symptoms of hypersensitivity reactions, dermatologic toxicity, hepatic sinusoidal obstruction syndrome, and CNS toxicity.</p></div>
<div class="block pha drugH1Div" id="F227137"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Thiotepa is an alkylating agent which produces cross-linking of DNA strands leading to inhibition of DNA, RNA, and protein synthesis; thiotepa is cell-cycle independent (Perry 2012)</p></div>
<div class="block phk drugH1Div" id="F227154"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 0.3 to 1.6 L/kg; penetrates into CSF (Maanen 2000); the mean volume of distribution following a single IV dose in pediatric patients receiving a 5 mg/kg dose was 1.2 L/kg or 30 L/m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~10% to 20%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic via cytochrome P450 system, primarily to the major (active) metabolite TEPA (Maanen 2000; Perry 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal:</p>
<p style="text-indent:-2em;margin-left:4em;">Pediatrics (5 mg/kg IV dose): Thiotepa: 1.7 hours; TEPA: 4 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults (20 mg to 250 mg/m<sup>2</sup> IV dose): Thiotepa: 1.4 to 3.7 hours; TEPA: 4.9 to 17.6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&lt;2% of thiotepa dose; &lt;11% of TEPA); dermal via sweat (Horn 1989).</p></div>
<div class="block phksp drugH1Div" id="F51160045"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Thiotepa and TEPA exposure increased 1.5-fold and 2.6-fold, respectively, following administration of multiple doses of 120 mg/m<sup>2</sup>/day in a patient with moderate renal impairment (CrCl 38 mL/minute), compared to patients with normal renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In two adult patients with liver metastases and moderate hepatic impairment receiving multiple thiotepa doses of 7 mg/kg (administered every 2 days with cyclophosphamide), thiotepa exposure increased by 1.6-fold and 1.8-fold compared to a patient with normal hepatic function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038841"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Tepadina | Thio-tepa</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Tepadina | Thiotepa riemser</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Thiotepa reach</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Tepadina | Thiotepa riemser</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Tepadina | Thiotepa riemser</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Tepadina</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Apeto | Tepadina | Tepakin | Thio spal p</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Tepadina | Thiotepa riemser</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Tepadina | Thiotepa lederle | Thiotepa riemser</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ledertepa | Tepadina | Thiotepa riemser</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Tepadina | Thiotepa riemser</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Tepadina | Thio-tepa | Thiotepa riemser</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Tepadina | Thiotepa genopharm</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Tepadina | Thiotepa riemser | Trav thiotepa</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Tepadina</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Tepadina | Thiotepa riemser</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Tepadina</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Tepadina | Thioplex</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Tepadina | Thioplex</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Tepadina</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Tepadina</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Tepadina</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Tepadina</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Tepadina | Thiomed</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ledertepa | Tepadina | Thiotepa riemser</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Tepadina | Thiotepa riemser</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Tepadina</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Tepadina | Thioplex</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Tepadina | Thioplex</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Tepadina</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Tepadina | Thiophosphamid</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Tepadina | Thiotepa riemser | Tifosyl</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Tepadina</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Tepadina</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Tepadina</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Tepadina</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Tepadina | Thiophosphamid</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Tepadina</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16524945">
<a name="16524945"></a>Abrey LE, Childs BH, Paleologos N, et al. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. <i>Neuro Oncol</i>. 2006;8(2):183-188.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/16524945/pubmed" id="16524945" target="_blank">16524945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24462742">
<a name="24462742"></a>Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. <i>Biol Blood Marrow Transplant</i>. 2014;20(5):600-616.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/24462742/pubmed" id="24462742" target="_blank">24462742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15531896">
<a name="15531896"></a>Bunin N, Aplenc R, Leahey A, et al. Outcomes of transplantation with partial T-cell depletion of matched or mismatched unrelated or partially matched related donor bone marrow in children and adolescents with leukemias. <i>Bone Marrow Transplant</i>. 2005;35(2):151-158. doi:10.1038/sj.bmt.1704754<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/15531896/pubmed" id="15531896" target="_blank">15531896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15611503">
<a name="15611503"></a>Chi SN, Gardner SL, Levy AS, et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. <i>J Clin Oncol</i>. 2004;22(24):4881-4887. doi:10.1200/JCO.2004.12.126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/15611503/pubmed" id="15611503" target="_blank">15611503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26092413">
<a name="26092413"></a>Cohen BH, Geyer JR, Miller DC, et al. Pilot study of intensive chemotherapy with peripheral hematopoietic cell support for children less than 3 years of age with malignant brain tumors, the CCG-99703 Phase I/II Study. A report from the Children's Oncology Group. <i>Pediatr Neurol</i>. 2015;53(1):31-46. doi:10.1016/j.pediatrneurol.2015.03.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/26092413/pubmed" id="26092413" target="_blank">26092413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15813508">
<a name="15813508"></a>DeAngelis LM and Butros D, “Leptomeningeal Metastasis,” <i>Cancer Invest</i>, 2005, 23(2):145-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/15813508/pubmed" id="15813508" target="_blank">15813508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28369839">
<a name="28369839"></a>DeFilipp Z, Li S, El-Jawahri A, et al. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. <i>Cancer</i>. 2017;123(16):3073-3079. doi:10.1002/cncr.30695<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/28369839/pubmed" id="28369839" target="_blank">28369839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18772215">
<a name="18772215"></a>de Lemos ML, Monfared S, Denyssevych T, et al, “Evaluation of Osmolality and pH of Various Concentrations of Methotrexate, Cytarabine, and Thiotepa Prepared in Normal Saline, Sterile Water for Injection, and Lactated Ringer's Solution for Intrathecal Administration,” <i>J Oncol Pharm Pract</i>, 2009, 15(1):45-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/18772215/pubmed" id="18772215" target="_blank">18772215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20167818">
<a name="20167818"></a>Dunkel IJ, Gardner SL, Garvin JH Jr, et al, “High-Dose Carboplatin, Thiotepa, and Etoposide With Autologous Stem Cell Rescue for Patients With Previously Irradiated Recurrent Medulloblastoma,” <i>Neuro Oncol</i>, 2010, 12(3):297-303.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/20167818/pubmed" id="20167818" target="_blank">20167818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21465637">
<a name="21465637"></a>Dupuis LL, Boodhan S, Sung L, et al. Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/23512831/pubmed" id="23512831" target="_blank">23512831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17668858">
<a name="17668858"></a>Fangusaro J, Finlay J, Sposto R, et al. Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience. <i>Pediatr Blood Cancer</i>. 2008;50(2):312-318. doi:10.1002/pbc.21307<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/17668858/pubmed" id="17668858" target="_blank">17668858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18802947">
<a name="18802947"></a>Finlay JL, Dhall G, Boyett JM, et al, "Myeloablative Chemotherapy With Autologous Bone Marrow Rescue in Children and Adolescents With Recurrent Malignant Astrocytoma: Outcome Compared With Conventional Chemotherapy: A Report From the Children's Oncology Group," <i>Pediatr Blood Cancer</i>, 2008, 51(6):806-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/18802947/pubmed" id="18802947" target="_blank">18802947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19998470">
<a name="19998470"></a>Gilheeney SW, Khakoo Y, Souweidane M, et al. Thiotepa/Topotecan/Carboplatin With Autologous Stem Cell Rescue in Recurrent/Refractory/Poor Prognosis Pediatric Malignancies of the Central Nervous System. <i>Pediatr Blood Cancer.</i> 2010;54(4):591-595.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/19998470/pubmed" id="19998470" target="_blank">19998470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19326417">
<a name="19326417"></a>Grodman H, Wolfe L, and Kretschmar C, “Outcome of Patients With Recurrent Medulloblastoma or Central Nervous System Germinoma Treated With Low Dose Continuous Intravenous Etoposide Along With Dose-Intensive Chemotherapy Followed by Autologous Hematopoietic Stem Cell Rescue,” <i>Pediatr Blood Cancer</i>, 2009, 53(1):33-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/19326417/pubmed" id="19326417" target="_blank">19326417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8445432">
<a name="8445432"></a>Grossman SA, Finkelstein DM, Ruckeschel JC, et al, “Randomized Prospective Comparison of Intraventricular Methotrexate and Thiotepa in Patients With Previously Untreated Neoplastic Meningitis. Eastern Cooperative Oncology Group,” <i>J Clin Oncol</i>, 1993, 11(3):561-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/8445432/pubmed" id="8445432" target="_blank">8445432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32328470">
<a name="32328470"></a>Guidi M, Giunti L, Buccoliero AM, Santi M, et al. Use of high-dose chemotherapy in front-line therapy of infants aged less than 12 months treated for aggressive brain tumors. <i>Front Pediatr</i>. 2020;8:135. doi: 10.3389/fped.2020.00135<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/32328470/pubmed" id="32328470" target="_blank">32328470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2491958">
<a name="2491958"></a>Heideman R, Cole D, Balis F, et al, "Phase I and Pharmacokinetic Evaluation of Thiotepa in the Cerebrospinal Fluid and Plasma of Pediatric Patients: Evidence for Dose-Dependent Plasma Clearance of Thiotepa," <i>Cancer Res</i>, 1989, 49(3):736-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/2491958/pubmed" id="2491958" target="_blank">2491958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2539058">
<a name="2539058"></a>Horn TD, Beveridge RA, Egorin MJ, Abeloff MD, Hood AF. Observations and proposed mechanism of N,N',N''-triethylenethiophosphoramide (thiotepa)-induced hyperpigmentation. <i>Arch Dermatol</i>. 1989;125(4):524-527.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/2539058/pubmed" id="2539058" target="_blank">2539058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19786650">
<a name="19786650"></a>Jacobson JO, Polovich M, McNiff KK, et al, "American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards," <i>J Clin Oncol</i>, 2009, 27(32):5469-75.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/19786650/pubmed" id="19786650" target="_blank">19786650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32203268">
<a name="32203268"></a>Kalwak K, Mielcarek M, Patrick K, et al. Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies. <i>Bone Marrow Transplant</i>. 2020;55(10):1996-2007. doi:10.1038/s41409-020-0869-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/32203268/pubmed" id="32203268" target="_blank">32203268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9482413">
<a name="9482413"></a>Kletzel M, Abella EM, Sandler ES, et al, "Thiotepa and Cyclophosphamide With Stem Cell Rescue for Consolidation Therapy for Children With High-Risk Neuroblastoma: A Phase I/II Study of the Pediatric Blood and Marrow Transplant Consortium," <i>J Pediatr Hematol Oncol</i>, 1998, 20(1):49-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/9482413/pubmed" id="9482413" target="_blank">9482413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11607767">
<a name="11607767"></a>Kushner BH, Cheung NK, Kramer K, et al, "Topotecan Combined With Myeloablative Doses of Thiotepa and Carboplatin for Neuroblastoma, Brain Tumors, and Other Poor-Risk Solid Tumors in Children and Young Adults," <i>Bone Marrow Transplant</i>, 2001, 28(6):551-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/11607767/pubmed" id="11607767" target="_blank">11607767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16400336">
<a name="16400336"></a>Kushner BH, Kramer K, Modak S, et al, "Topotecan, Thiotepa, and Carboplatin for Neuroblastoma: Failure to Prevent Relapse in the Central Nervous System," <i>Bone Marrow Transplant</i>, 2006, 37(3):271-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/16400336/pubmed" id="16400336" target="_blank">16400336</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Maanen MJ, Smeets CJ, and Beijnen JH, “Chemistry, Pharmacology and Pharmacokinetics of N,N',N", -Triethylenethiophosphoramide (ThioTEPA)," <i>Cancer Treat Rev</i>, 2000, 26(4):257-68.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27715384">
<a name="27715384"></a>Mussetti A, Kernan NA, Prockop SE, et al. Allogeneic hematopoietic stem cell transplantation for nonmalignant hematologic disorders using chemotherapy-only cytoreductive regimens and T-cell-depleted grafts from human leukocyte antigen-matched or -mismatched donors. <i>Pediatr Hematol Oncol</i>. 2016;33(6):347-358. doi:10.1080/08880018.2016.1204399<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/27715384/pubmed" id="27715384" target="_blank">27715384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28905508">
<a name="28905508"></a>Osorio DS, Dunkel IJ, Cervone KA, et al. Tandem thiotepa with autologous hematopoietic cell rescue in patients with recurrent, refractory, or poor prognosis solid tumor malignancies. <i>Pediatr Blood Cancer</i>. 2018;65(1):10.1002/pbc.26776. doi:10.1002/pbc.26776<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/28905508/pubmed" id="28905508" target="_blank">28905508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31454045">
<a name="31454045"></a>Park JR, Kreissman SG, London WB, et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. <i>JAMA</i>. 2019;322(8):746-755. doi:10.1001/jama.2019.11642<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/31454045/pubmed" id="31454045" target="_blank">31454045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30729654">
<a name="30729654"></a>Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: a clinical practice guideline. <i>Pediatr Blood Cancer</i>. 2019;66(5):e27646. doi:10.1002/pbc.27646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/30729654/pubmed" id="30729654" target="_blank">30729654</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Perry MC. Chemotherapeutic agents: Thiotepa. <i>The Chemotherapy Source Book</i>. 5th ed. Philadelphia, PA: 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27664248">
<a name="27664248"></a>Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133. doi: 10.1093/annonc/mdw270.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/27664248/pubmed" id="27664248" target="_blank">27664248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24115731">
<a name="24115731"></a>Shukla N, Kobos R, Renaud T, Steinherz LJ, Steinherz PG. Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia. <i>Pediatr Blood Cancer</i>. 2014;61(3):431-435. doi:10.1002/pbc.24789<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/24115731/pubmed" id="24115731" target="_blank">24115731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18413641">
<a name="18413641"></a>Soussain C, Hoang-Xuan K, Taillandier L, et al, “Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire,” <i>J Clin Oncol</i>, 2008, 26(15):2512-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/18413641/pubmed" id="18413641" target="_blank">18413641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27184623">
<a name="27184623"></a>Spitzer B, Perales MA, Kernan NA, et al. Second allogeneic stem cell transplantation for acute leukemia using a chemotherapy-only cytoreduction with clofarabine, melphalan, and thiotepa. <i>Biol Blood Marrow Transplant</i>. 2016;22(8):1449-1454. doi:10.1016/j.bbmt.2016.05.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/27184623/pubmed" id="27184623" target="_blank">27184623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20205253">
<a name="20205253"></a>Steinherz PG, Shukla N, Kobos R, Steinherz L. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia. <i>Pediatr Blood Cancer</i>. 2010;54(5):687-693. doi:10.1002/pbc.22321<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/20205253/pubmed" id="20205253" target="_blank">20205253</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Tepadina (thiotepa) [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; March 2020.</div>
</li>
<li>
<div class="reference">
                  Tepadina (thiotepa) [product monograph]. Lugano, Switzerland: Adienne SA; December 2021.</div>
</li>
<li>
<div class="reference">
                  Thiotepa [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; February 2015.</div>
</li>
<li>
<div class="reference">
                  Thiotepa [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; January 2019.</div>
</li>
<li>
<div class="reference">
                  Thiotepa [prescribing information]. Piscataway, NJ: Novadoz Pharmaceuticals; February 2020.</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30185131">
<a name="30185131"></a>Van Schandevyl G, Bauters T. Thiotepa-induced cutaneous toxicity in pediatric patients: Case report and implementation of preventive care guidelines. <i>J Oncol Pharm Pract</i>. 2019;25(3):689-693. doi:10.1177/1078155218796905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/30185131/pubmed" id="30185131" target="_blank">30185131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10561223">
<a name="10561223"></a>Zecca M, Pession A, Messina C, et al. Total body irradiation, thiotepa, and cyclophosphamide as a conditioning regimen for children with acute lymphoblastic leukemia in first or second remission undergoing bone marrow transplantation with HLA-identical siblings. <i>J Clin Oncol</i>. 1999;17(6):1838-1846. doi:10.1200/JCO.1999.17.6.1838<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thiotepa-pediatric-drug-information/abstract-text/10561223/pubmed" id="10561223" target="_blank">10561223</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12838 Version 300.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
